LifeSciences BC > News > Industry News > 2015 > LifeSciences BC Responds to CADTH Report on Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

Print Friendly

October 29, 2015
Brian O’Rourke, President and Chief Executive Officer,
Canadian Agency for Drugs & Technologies in Health
865 Carling Ave.,
Ottawa, ON K1S 5S8

Re.: Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions

Dear Mr. O’Rourke:

LifeSciences BC is a member driven organization which supports and represents the interests of the human life science community in British Columbia. We are a not-for-profit association sustained by our membership which includes: Academia, R&D, Health Foundations and Organizations, SME’s, bio pharmaceuticals and bioinformatics along with other non-profit life science bodies located here and around the globe.

I write to you today on behalf of our membership who have critical concerns regarding the recent Anti-VEGF Therapeutic Review Draft Science Report on Anti–Vascular Endothelial Growth Factor Drugs for Retinal Conditions. We are aware and have been in contact with, both Canada’s Research-Based Pharmaceutical Companies (Rx&D) and BIOTECanada, who have undertaken to submit a response on behalf of researched based pharmaceutical companies.

LifeSciences BC fully supports and endorses the consultation response from Rx&D and BIOTECanada and we request that the recommendations identified in their considered response, be addressed in a timely and regulatory efficient manner.

Sincerely,
Paul Drohan,
President & CEO,
LifeSciences BC